~~<i id='9E630D1835'><strike id='9E630D1835'><tt id='9E630D1835'><pre id='9E630D1835'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

fashion

author：fashion 2025-09-28 00:47:39 - browse：7174

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Why palliative psychiatry is worth discussing

hotspot

focus

hotspot

focus

explore

Wikipedia

AFP/GettyImagesMostofthetime,it’seasytobeintheplacebogroup ofaclinicaltrial:nosideeffects,minimalann

WSS

R1 RCM gets $5.8 billion buyout offer from private equity firm

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

6 phony surgeries that take placebo to the extreme

Congress needs to close a vaccine

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

explore

fashion

hotspot

Affirmative action in medical school literally saved lives

CMS got Medicare Advantage quality rating wrong, judge rules

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Community Health Systems hospitals under DOJ investigation

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth CEO's Medicaid comments send insurer stocks diving

United colonoscopy coverage change 'may cost lives,' doctors say

FTC loses bid to block Novant's North Carolina hospital merger

Alkermes shareholders re

Alabama hospital puts IVF treatments on hold

focus

'Little Tech' descents on D.C., wanting a say in how AI is regulated

With competition flaring, obesity drug hits goal in liver disease study

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Eli Lilly’s Zepbound improved liver scarring in mid

Why palliative psychiatry is worth discussing

Structure Therapeutics oral GLP

hotspot

focus

explore

Wikipedia